Scarica l'app Stockscreener
485.62
3.25%
-14.87
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
Reshma Kewalramani named among Time magazine's 100 most influential people - Firstpost
Vertex’s Attempt to Redefine AKS Falls Short: Key Insights for Pharma Manufacturers - ArentFox Schiff
Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $617 From $615, Maintains Buy Rating - MarketScreener
Stock Market Whiplash: 3 Growth Stocks That Are No-Brainer Buys on the Bounce - The Motley Fool
Vertex Pharmaceuticals (VRTX) Celebrated for Groundbreaking CF R - GuruFocus
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? - AOL.com
Lobbying Update: $20,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Nasdaq
Pharma Tariffs Are Coming. Investors Underestimate the Risk. - Barron's
Vertex researcher recognized by the Canada Gairdner International Award - Vertex Pharmaceuticals
CrowdStrike, Robinhood, Palo Alto Networks And A Health Care Stock On CNBC's 'Final Trades' - Benzinga
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canad - GuruFocus
Vertex Researcher, Paul Negulescu Ph.D., Receives The 2025 Canada Gairdner International Award For Pioneering Research And Discovery Of Medicines For Cystic Fibrosis - MarketScreener
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis - Business Wire
Vertex Pharmaceuticals (VRTX) Stock Moves -1.41%: What You Should Know - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Surged on Increased Demand for its Cystic Fibrosis (CF) Franchise - Insider Monkey
Vertex Pharmaceuticals gets EU nod to expand label for cystic fibrosis treatment - MSN
‘Put On Your Life Vest’: Pharma Tariffs Are Coming - BioSpace
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know - MSN
Morgan Stanley Adjusts PT on Vertex Pharmaceuticals to $462 From $459, Keeps Equalweight Rating - MarketScreener
An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 41% Undervalued - Yahoo Finance
Vertex raises pay of CEO Reshma Kewalramani by 4% to $21.5M - Fierce Pharma
Vertex non-opioid painkiller Journavx gets mixed ICER review - MSN
Jim Cramer Calls Vertex Pharmaceuticals Incorporated (VRTX) “Terrific” With “Revolutionary Pain Drug” - Insider Monkey
Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Long Term Growth Stock to Buy According to Billionaires? - Yahoo Finance
Is Vertex Pharmaceuticals Stock a Buy? - MSN
Vertex secures expanded EU approval for Kaftrio - The Pharma Letter
VRTX Secures Nod for Expanded Use of CF Drug Kaftrio in Europe - Yahoo Finance
Jim Cramer Nailed These 11 Stock Picks - Insider Monkey
Vertex to Announce First Quarter 2025 Financial Results on May 5th - BioSpace
Vertex Gains European Approval For Expanded Use Of KAFTRIO In Treating Cystic Fibrosis - Nasdaq
European Commission Expands Approval for Vertex's Kaftrio (VRTX) - GuruFocus
Vertex Pharmaceuticals Says EU Approves Kaftrio Label Expansion in Cystic Fibrosis - MarketScreener
EU approves expanded use of Vertex’s cystic fibrosis drug - Investing.com
Vertex's Journavx Launch Sparks Optimism, Analyst Sees 'Two Potential Upside Levers' - Benzinga
2 Stocks to Buy if You're Worried About a Recession - Yahoo Finance
Vertex Pharmaceuticals Sets Key Q1 2025 Earnings Date: What Investors Must Know - Stock Titan
Vertex Pharmaceuticals: A Look At Their Pain Therapy Program (NASDAQ:VRTX) - Seeking Alpha
Vertex Pharmaceuticals - drugdiscoverytrends.com
10 Best Health Care Stocks to Buy for 2025 - Money/ US News
Layoff Tracker: Relay Will Cut 70 Employees, Affecting Research Budget by 75% - BioSpace
Bank of America Increases Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $567.00 - MarketBeat
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Vertex Pharmaceuticals: How a Human-Centric Digital Strategy Transforms Supply Chain Agility - Logistics Viewpoints -
Wells Fargo Remains a Hold on Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Vertex Pharmaceuticals' Human-Centric Approach to Digital Transformation - ARC Advisory
Petri Dish: Vertex halts type 1 diabetes trial; Watertown manufacturer sold - The Business Journals
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Apellis Pharmaceuticals (APLS) - The Globe and Mail
Vertex Pharmaceuticals (VRTX): Company Profile, Stock Price, News, Rankings - Fortune
Judge Blocks Vertex From Funding Fertility Preservation Services - Bloomberg Law News
Careers | Inclusion, Diversity and Equity - Vertex Pharmaceuticals
Is Vertex Pharmaceuticals Gaining or Losing Market Support? - Benzinga
Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Gene-Editing Stock to Buy? - Insider Monkey
DC court backs HHS in rejecting Vertex's proposed fertility support program for Casgevy patients - Fierce Pharma
VRTX Provides Mixed Updates for Type 1 Diabetes Pipeline Candidates - TradingView
RBC Adjusts Price Target on Vertex Pharmaceuticals to $420 From $408, Maintains Sector Perform Rating - MarketScreener
Vertex Pharmaceuticals price target raised to $420 from $408 at RBC Capital - TipRanks
0.64%
1.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):